脊索样脑膜瘤与其他WHO 2级脑膜瘤亚型相比长期预后更佳
本研究纳入2010至2018年609例WHO 2级脑膜瘤患者(非典型543例、脊索样36例、透明细胞30例),比较临床病理特征与长期预后。脊索样脑膜瘤的无进展生存期(P=0.022)和总生存期(P=0.0056)优于非脊索样肿瘤,但无进展生存期仍差于WHO 1级脑膜瘤(P<0.001)。NF2(20.6%)和KMT2C(26.5%)改变与脊索样脑膜瘤更差的无进展生存期相关。
要点
- 脊索样脑膜瘤全切除率高于非典型和透明细胞脑膜瘤(P=0.033)。
- 脊索样脑膜瘤Ki-67指数更低、孕激素受体阳性率更高(P<0.001;P=0.034)。
- 脊索样脑膜瘤无进展生存期优于非脊索样肿瘤(P=0.022),但差于WHO 1级(P<0.001)。
核心结论
- 脊索样脑膜瘤患者术后长期结局优于其他WHO 2级亚型,较低Ki-67指数、较高孕激素受体阳性率、更高切除程度和较低NF2改变频率可能 contribute 于其良好临床结局。
研究设计与样本
- 研究纳入2010至2018年连续609例WHO 2级脑膜瘤患者,其中非典型脑膜瘤543例、脊索样脑膜瘤36例、透明细胞脑膜瘤30例,比较三种亚型的临床病理特征和长期结局,并对脊索样脑膜瘤病例进行脑膜瘤相关基因靶向panel测序。
主要发现
- 透明细胞脑膜瘤患者较非典型脑膜瘤(P<0.001)和脊索样脑膜瘤(P=0.016)患者显著年轻。
- 脊索样脑膜瘤较非典型和透明细胞脑膜瘤更常接受全切除(P=0.033)。
- 脊索样脑膜瘤的Ki-67指数低于非典型和透明细胞脑膜瘤(P<0.001),孕激素受体阳性率高于非典型和透明细胞脑膜瘤(P=0.034)。
- 脊索样脑膜瘤的无进展生存期(P=0.022)和总生存期(P=0.0056)优于非脊索样肿瘤,但无进展生存期仍差于WHO 1级脑膜瘤(P<0.001)。
- NF2改变(20.6%)和KMT2C改变(26.5%)与脊索样脑膜瘤更差的无进展生存期相关(NF2 P=0.013;KMT2C P=0.021)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: WHO grade 2 meningiomas, including atypical, chordoid, and clear cell subtypes, form a heterogenous group of meningiomas with varying aggressiveness and clinical behavior. OBJECTIVE: To demonstrate the differences of clinical-histopathological characteristics and long-term outcomes among these 3 subtypes. METHODS: A total of 609 consecutive patients diagnosed with WHO grade 2 meningiomas (543 atypical meningiomas [AMs], 36 chordoid meningiomas [CMs], and 30 clear cell meningiomas [CCMs]) from 2010 to 2018 were enrolled in this study. We compared the clinical-histopathological characteristics and long-term outcomes in these 3 subtypes and assessed survival differences among the subtypes. Targeted panel sequencing of meningioma-relevant genes was performed in the cases of CM. RESULTS: The patients with CCM were significantly younger than those with AM ( P < .001) and CM ( P = .016). CMs were more likely to receive gross total resection than AMs and CCMs ( P = .033). The Ki-67 index was lower ( P < .001) while the progesterone receptors-positive rate was higher ( P = .034) in CM than in AM and CCM. Importantly, survival analysis demonstrated that CM had better progression-free survival ( P = .022) and overall survival ( P = .0056) than non-CM tumors. However, the PFS of CM was still worse than WHO grade 1 meningiomas ( P < .001). Alterations in NF2 (20.6%) and KMT2C (26.5%) were associated with poorer PFS in CM ( P = .013 for NF2 ; P = .021 for KMT2C ). CONCLUSION: Patients with CM had better long-term postoperative outcomes than the other WHO grade 2 subtypes. A lower Ki-67 index, higher PR status, higher extent of resection, and lower frequency of NF2 alteration might contribute to favorable clinical outcomes of CM.
引用
- Ren L, Hua L, Deng J, et al. Favorable Long-Term Outcomes of Chordoid Meningioma Compared With the Other WHO Grade 2 Meningioma Subtypes. Neurosurgery. 2022. PMID: 36512828. doi:10.1227/neu.0000000000002272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。